Cloudbreak Pharma Withdraws IND Application For CBT-009 Phase 3 Trial In China

ReutersMar 19, 2026 3:26 PM

March 19 (Reuters) - Cloudbreak Pharma Inc 2592.HK:

WITHDRAWS IND APPLICATION FOR PHASE 3 TRIAL IN CHINA
TO REASSESS CLINICAL DEVELOPMENT STRATEGY FOR CBT-009
EXPECTS PHASE 3 MRCT COMPLETION FOR CBT-001 IN Q3 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

What Is Palantir? Can Palantir’s Stock Price Return to $200 in 2026?

TradingKey - In today’s highly competitive technology landscape, Palantir (PLTR), as a company with a core focus on big data and artificial intelligence, has garnered widespread attention through its unique technological advantages and market positioning.

Micron Plunges 10%, Earnings Beat Expectations, Stock Price Falls 30% Consecutively, Can AI Memory Chips Still Be Bought?

TradingKey — Micron Technology’s (MU) recent stock price performance has become a microcosm of shifting sentiment within the AI memory sector. Despite reporting robust earnings, the stock has weakened steadily following the announcement, marking a cumulative decline of nearly 30%. The market is now

IREN, NBIS, and CRWV: The Rise of Neoclouds in the AI Infrastructure Boom

Iris Energy (IREN), Nebius (NBIS) and Coreweave (CRWV) are frequently grouped due to their shared focus on AI infrastructure

Hedge Fund Tycoon Calls ‘Ten-Fold Opportunity,’ Fannie and Freddie Shares Both Surge Over 45%.

TradingKey - During Monday's U.S. Eastern trading session, shares of U.S. mortgage giants Fannie Mae and Freddie Mac experienced a rare surge, boosted by public bullish comments from renowned hedge fund manager Bill Ackman. Fannie Mae (FNMA) shares soared by more than 50%, while Freddie Mac (FMCC) jumped approximately 47%, becoming the focus of the market.

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

Tradingkey

KeyAI

